Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ataxia | 8 | 2024 | 80 | 4.330 |
Why?
|
| Tremor | 8 | 2024 | 98 | 4.260 |
Why?
|
| Fragile X Syndrome | 9 | 2024 | 190 | 4.180 |
Why?
|
| Postural Balance | 5 | 2025 | 112 | 2.820 |
Why?
|
| Psychomotor Performance | 3 | 2025 | 165 | 1.620 |
Why?
|
| Huntington Disease | 2 | 2025 | 48 | 1.500 |
Why?
|
| Gait | 5 | 2020 | 384 | 1.240 |
Why?
|
| Accidental Falls | 3 | 2020 | 105 | 1.240 |
Why?
|
| Fragile X Mental Retardation Protein | 5 | 2016 | 112 | 1.230 |
Why?
|
| Heterozygote | 4 | 2020 | 90 | 1.090 |
Why?
|
| Gait Disorders, Neurologic | 2 | 2020 | 120 | 1.060 |
Why?
|
| Cerebral Cortex | 3 | 2025 | 132 | 0.980 |
Why?
|
| Parietal Lobe | 1 | 2025 | 12 | 0.940 |
Why?
|
| Prefrontal Cortex | 1 | 2025 | 107 | 0.880 |
Why?
|
| Male | 18 | 2025 | 12663 | 0.770 |
Why?
|
| Walking Speed | 2 | 2020 | 35 | 0.770 |
Why?
|
| Databases, Factual | 2 | 2021 | 310 | 0.730 |
Why?
|
| Female | 17 | 2025 | 13147 | 0.720 |
Why?
|
| Walking | 2 | 2022 | 235 | 0.720 |
Why?
|
| Aged | 10 | 2025 | 7660 | 0.640 |
Why?
|
| Middle Aged | 10 | 2025 | 7981 | 0.630 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2020 | 4 | 0.630 |
Why?
|
| Movement Disorders | 2 | 2020 | 57 | 0.630 |
Why?
|
| Nootropic Agents | 1 | 2020 | 11 | 0.630 |
Why?
|
| Attention | 1 | 2020 | 101 | 0.620 |
Why?
|
| Phenotype | 3 | 2016 | 260 | 0.600 |
Why?
|
| Humans | 17 | 2025 | 23207 | 0.580 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 804 | 0.550 |
Why?
|
| Executive Function | 1 | 2018 | 94 | 0.540 |
Why?
|
| Cyclodextrins | 1 | 2018 | 7 | 0.540 |
Why?
|
| Niemann-Pick Disease, Type C | 1 | 2018 | 21 | 0.530 |
Why?
|
| Adult | 7 | 2025 | 6959 | 0.530 |
Why?
|
| Receptors, Estrogen | 5 | 1995 | 62 | 0.420 |
Why?
|
| Hyperkinesis | 1 | 2013 | 8 | 0.410 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 17 | 0.400 |
Why?
|
| Adolescent | 4 | 2021 | 1884 | 0.400 |
Why?
|
| Cognition Disorders | 1 | 2018 | 726 | 0.390 |
Why?
|
| Neuropsychological Tests | 3 | 2020 | 917 | 0.340 |
Why?
|
| Biomechanical Phenomena | 4 | 2022 | 538 | 0.340 |
Why?
|
| Child | 3 | 2021 | 1160 | 0.330 |
Why?
|
| Reference Values | 2 | 2021 | 169 | 0.320 |
Why?
|
| Walk Test | 2 | 2020 | 10 | 0.320 |
Why?
|
| Young Adult | 3 | 2021 | 1657 | 0.300 |
Why?
|
| Child, Preschool | 2 | 2021 | 569 | 0.290 |
Why?
|
| Hippocampus | 4 | 1995 | 200 | 0.290 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2025 | 13 | 0.240 |
Why?
|
| Prodromal Symptoms | 1 | 2024 | 17 | 0.210 |
Why?
|
| Cognition | 2 | 2020 | 1026 | 0.190 |
Why?
|
| Parkinson Disease | 2 | 2020 | 595 | 0.180 |
Why?
|
| Case-Control Studies | 2 | 2020 | 485 | 0.180 |
Why?
|
| Shoes | 1 | 2022 | 31 | 0.180 |
Why?
|
| Biomarkers | 1 | 2024 | 485 | 0.180 |
Why?
|
| Retrospective Studies | 2 | 2020 | 2993 | 0.170 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2020 | 4 | 0.160 |
Why?
|
| Time and Motion Studies | 1 | 2020 | 17 | 0.160 |
Why?
|
| Glucosylceramidase | 1 | 2020 | 13 | 0.160 |
Why?
|
| Foot | 1 | 2020 | 40 | 0.160 |
Why?
|
| Arm | 1 | 2020 | 68 | 0.150 |
Why?
|
| Range of Motion, Articular | 2 | 2020 | 565 | 0.150 |
Why?
|
| Animals | 7 | 2016 | 3302 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2020 | 369 | 0.140 |
Why?
|
| Mutation | 1 | 2020 | 330 | 0.140 |
Why?
|
| Infusions, Spinal | 1 | 2018 | 5 | 0.140 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 3865 | 0.140 |
Why?
|
| Spinal Puncture | 1 | 2018 | 23 | 0.130 |
Why?
|
| Motor Activity | 1 | 2020 | 274 | 0.130 |
Why?
|
| Brain Tissue Transplantation | 2 | 1993 | 15 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2016 | 30 | 0.120 |
Why?
|
| Time Factors | 1 | 2020 | 1264 | 0.120 |
Why?
|
| Posture | 1 | 2016 | 56 | 0.120 |
Why?
|
| Computers | 1 | 2015 | 14 | 0.120 |
Why?
|
| Neuroimaging | 1 | 2016 | 105 | 0.120 |
Why?
|
| Early Diagnosis | 1 | 2015 | 51 | 0.120 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2015 | 42 | 0.120 |
Why?
|
| Reaction Time | 1 | 2015 | 81 | 0.110 |
Why?
|
| Animals, Newborn | 3 | 1993 | 41 | 0.110 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 64 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2015 | 216 | 0.110 |
Why?
|
| Disability Evaluation | 1 | 2016 | 225 | 0.110 |
Why?
|
| Sexual Behavior, Animal | 1 | 1994 | 1 | 0.110 |
Why?
|
| Pituitary-Adrenal System | 1 | 1994 | 9 | 0.110 |
Why?
|
| Receptors, Progesterone | 1 | 1994 | 26 | 0.110 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1994 | 21 | 0.110 |
Why?
|
| Arousal | 1 | 1994 | 48 | 0.110 |
Why?
|
| Disease Progression | 1 | 2016 | 547 | 0.110 |
Why?
|
| RNA, Messenger | 1 | 1995 | 283 | 0.110 |
Why?
|
| Rats | 6 | 1995 | 624 | 0.100 |
Why?
|
| Task Performance and Analysis | 1 | 2013 | 44 | 0.100 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 369 | 0.100 |
Why?
|
| Cerebellar Diseases | 1 | 2013 | 8 | 0.100 |
Why?
|
| Movement | 1 | 2013 | 106 | 0.100 |
Why?
|
| Treatment Outcome | 1 | 2020 | 2943 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 875 | 0.090 |
Why?
|
| Neurons | 2 | 1995 | 273 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2016 | 1467 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 1037 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1995 | 314 | 0.050 |
Why?
|
| Fetal Tissue Transplantation | 2 | 1993 | 22 | 0.050 |
Why?
|
| Estradiol | 2 | 1993 | 52 | 0.050 |
Why?
|
| Mechanical Phenomena | 1 | 2022 | 21 | 0.040 |
Why?
|
| Pregnancy | 2 | 1993 | 324 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 598 | 0.040 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 1995 | 1 | 0.030 |
Why?
|
| N-Methylaspartate | 1 | 1995 | 2 | 0.030 |
Why?
|
| Receptors, AMPA | 1 | 1995 | 7 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1995 | 10 | 0.030 |
Why?
|
| Sex Differentiation | 1 | 1995 | 2 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1995 | 19 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1995 | 24 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1995 | 49 | 0.030 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 1994 | 7 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1994 | 5 | 0.030 |
Why?
|
| Aging | 2 | 1993 | 1180 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1992 | 25 | 0.030 |
Why?
|
| Gene Expression | 1 | 1995 | 180 | 0.030 |
Why?
|
| Cytosol | 2 | 1992 | 41 | 0.030 |
Why?
|
| Brain Mapping | 1 | 1994 | 124 | 0.030 |
Why?
|
| Transplantation, Heterotopic | 1 | 1993 | 7 | 0.030 |
Why?
|
| Preoptic Area | 1 | 1993 | 5 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 1993 | 57 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 1994 | 227 | 0.020 |
Why?
|
| Age Factors | 1 | 1995 | 651 | 0.020 |
Why?
|
| Calcium | 1 | 1995 | 370 | 0.020 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 806 | 0.020 |
Why?
|
| Diethylstilbestrol | 1 | 1990 | 1 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 1990 | 3 | 0.020 |
Why?
|
| Ethinyl Estradiol | 1 | 1990 | 2 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 1990 | 3 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1990 | 70 | 0.020 |
Why?
|
| Kinetics | 1 | 1990 | 176 | 0.020 |
Why?
|
| Sex Factors | 1 | 1990 | 399 | 0.020 |
Why?
|
| Receptors, Glutamate | 1 | 1995 | 1 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 1995 | 21 | 0.010 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 1995 | 22 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1995 | 463 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1992 | 198 | 0.010 |
Why?
|